Table 1.
Baseline characteristics of the study subjects
| Budesonide/Salbutam ol group (n = 45) |
Budesonide/Formoterol group (n = 45) | |
|---|---|---|
| Age, years | 8.6 ± 2.3 | 8.9 ± 2.13 |
| Sex- male/female, n | 33/12 | 30/15 |
| Weight, kg | 23.3 ± 6.3 | 25 ± 8.2 |
| Height, cm | 127.2 ± 14.2 | 129 ± 13.5 |
| Duration of symptoms, days | 6.0 ± 3.6 | 6.1 ± 4.1 |
| Cough | 44 (98%) | 44 (98%) |
| Breathlessness | 45 (100%) | 41 (91%) |
| Night symptoms | 27 (60%) | 33 (73%) |
| Wheeze | 24 (53%) | 23 (51%) |
| Frequency of exacerbations | 3 [2-6] | 3 [2-6] |
| per year [median(IQR)] | ||
| Type of asthma | ||
| 1. Mild intermittent | 19 (42%) | 18 (40%) |
| 2. Mild persistent | 15 (33%) | 15 (33%) |
| 3. Moderate persistent | 10 (22%) | 12 (27%) |
| 4. Severe persistent | 1 (2%) | 0 (0%) |
| MPIS | 7.3 ± 1.2 | 7.2 ± 1.0 |
| FEV1 (% predicted) | 58.2 ± 18.1; N = 43 | 55.9 ± 14.8 |
| PEFR (% predicted) | 55.5 ± 21.5; N = 43 | 58.6 ± 16.3 |
| FVC (% predicted) | 61.5 ± 28.3; N = 43 | 53.8 ± 20.8 |
| FEF50 (% predicted) | 65.9 ± 37.6; N = 43 | 70.6 ± 23.7 |
| FEV1/FVC (% predicted) | 84.9 ± 21.9; N = 43 | 91.4 ± 14.5 |
MPIS: Modified Pulmonary Index Score; Values are Mean ± SD, unless indicated